Education
About Us
Working with TipRanks
Follow Us
Nucana Plc (NCNA)
:NCNA
NCNA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.12 - $2,158.00
Previous CloseN/A
Volume88.96K
Average Volume (3M)1.19M
Market Cap
$8.99M
Enterprise Value$420.68K
Total Cash (Recent Filing)$3.95M
Total Debt (Recent Filing)$173.00K
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Aug 14, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.40
Shares Outstanding11,332
10 Day Avg. Volume794,351
30 Day Avg. Volume1,192,974
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.02
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
Nucana News
NCNA FAQ
What was Nucana Plc’s price range in the past 12 months?
Nucana Plc lowest stock price was $4.12 and its highest was $2158.00 in the past 12 months.
What is Nucana Plc’s market cap?
Nucana Plc’s market cap is $8.99M.
When is Nucana Plc’s upcoming earnings report date?
Nucana Plc’s upcoming earnings report date is Aug 14, 2025 which is tomorrow.
How were Nucana Plc’s earnings last quarter?
Nucana Plc released its earnings results on Jun 02, 2025. The company reported -$5.4 earnings per share for the quarter, missing the consensus estimate of -$2.7 by -$2.7.
Is Nucana Plc overvalued?
According to Wall Street analysts Nucana Plc’s price is currently Overvalued.
Does Nucana Plc pay dividends?
Nucana Plc does not currently pay dividends.
What is Nucana Plc’s EPS estimate?
Nucana Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nucana Plc have?
Nucana Plc has 11,332 shares outstanding.
What happened to Nucana Plc’s price movement after its last earnings report?
Nucana Plc reported an EPS of -$5.4 in its last earnings report, missing expectations of -$2.7. Following the earnings report the stock price went up 57.368%.
Which hedge fund is a major shareholder of Nucana Plc?
Currently, no hedge funds are holding shares in NCNA
Company Description
Nucana Plc
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
Technical Analysis
TNF Pharmaceuticals
―
Scinai Immunotherapeutics
―
CNS Pharmaceuticals
―
Vincerx Pharma Inc
―
ELEVAI Labs Inc.
―
Ownership Overview
11.00%
Insiders
<0.01% Mutual Funds
0.03% Other Institutional Investors
99.97% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---